We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amicus Therapeutics has announced plans to present the results of preclinical studies of Plicera as an investigational treatment for Gaucher disease, a lysosomal storage disorder.
Talecris Biotherapeutics announced that the first patient has been enrolled in its Phase I/II clinical trial investigating the ability of plasmin to treat acute peripheral arterial occlusion.
Acambis has begun testing its investigational West Nile virus vaccine, ChimeriVax-West Nile, in older adults, those most in need of protection against West Nile virus, the company announced.
Cell Therapeutics announced it will file for a special protocol assessment (SPA) with the FDA for the design of a Phase III trial of a combination therapy for women with advanced lung cancer.
Advanced Magnetics announced it has completed enrollment in a clinical study of ferumoxytol in 230 dialysis-dependent chronic kidney disease (CKD) patients.
Wockhardt announced it has received FDA approval to market generic painkiller tablets containing a combination of dextropropoxyphene napsylate and acetaminophen in the U.S.
Astellas Pharma announced that its U.S. subsidiary has received an approvable letter from the FDA in response to the company's supplemental new drug application (sNDA) for Prograf plus mycophenolate mofetil (MMF) as an adjunct therapy for the prophylaxis of organ rejection in kidney transplant patients.